BUSINESS AREA

Area of product & research

COVID19 / MERS Co-V / SARS Co-V
Rhinovirus
Herpes Simplex Virus
Infuenza Virus A·B·C
Other Medicines

Pipeline

BOSON Bioscience's R&D program focuses on the following future plans. With a sense of the mission that the impossible is not just conquered, we develop substances that respond to life-threatening viral diseases, in vitro, in-vivo, and clinical trials, and then commercialize them through approval of the authorities.

We aim for an innovative enterprise that establishes and drives the following business models.

Viral Diseases

  • 1

    Emerging Virus

  • 2

    Rhino virus

  • 3

    Herpes Simplex Virus

  • 4

    Anti-bacteria

  • 5

    Infuenza Virus A·B·C

    - Viral Diseases Infuenza

Independent development area

Innovative approach to the development of COVID-19 treatment process, drug delivery system (DDS) development for flu prevention and treatment, herpes simplex and herpes labialis studies

BOSON Bioscience's research program has achieved a lot in developing certain treatments that were once thought impossible. We are always leading the way in treating, developing and commercializing various diseases around the world by introducing new products into clinical trials.